Related Experiment Videos
Insights
Bacillus Calmette-Guérin (BCG) immunotherapy did not extend remission duration for children with acute lymphocytic leukemia (ALL). Chemotherapy proved more effective in maintaining remission compared to BCG or no further treatment.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Hematologic Malignancies
Background:
- Acute lymphocytic leukemia (ALL) is a common childhood cancer.
- Achieving remission after initial treatment is crucial for long-term outcomes.
- Maintenance therapy plays a vital role in preventing relapse.
Purpose of the Study:
- To evaluate the efficacy of Bacillus Calmette-Guérin (BCG) immunotherapy in prolonging remission in children with ALL.
- To compare BCG immunotherapy with continued chemotherapy and no further therapy in maintaining remission.
Main Methods:
- A randomized controlled trial involving children with ALL in remission.
- Patients were assigned to receive no further therapy, BCG, or maintenance chemotherapy.
- A secondary randomization occurred for patients on chemotherapy who remained in remission after 8 months.
Main Results:
- BCG immunotherapy did not significantly prolong remission duration compared to no further therapy in the primary randomization (median 4 vs. 4.3 months).
- Chemotherapy significantly extended remission duration, with medians not reached by 8 months in the primary and secondary randomizations.
- BCG was ineffective in maintaining drug-induced remissions, regardless of the stage of remission.
Conclusions:
- BCG immunotherapy is ineffective for prolonging remission in children with acute lymphocytic leukemia.
- Maintenance chemotherapy is superior to BCG or no therapy in sustaining remission for pediatric ALL patients.
- Further research may be needed to explore alternative immunotherapy strategies for ALL maintenance.
Abstract:
Children with acute lymphocytic leukemia, who were in remission after induction with prednisone and vincristine and consolidation with intravenous methotrexate, were randomized into three groups receiving (1) no further therapy, (2) BCG, and (3) chemotherapy with biweekly methotrexate and monthly prednisone and vincristine. Children continuing in remission after 8 mo on chemotherapy in group 3 were rerandomized into three similar groups, i.e., no therapy, BCG, and chemotherapy. In the primary randomization, the median duration of remission was identical in the groups receiving no therapy or BCG, (4 and 4.3 mo respectively), and both were significantly less than the median duration of remission on chemotherapy which had not been reached prior to secondary randomization at 8 mo. Results of secondary randomization were similar to those of primary randomization. As used in this study, BCG was ineffective in prolonging drug-induced remissions either early in remission or when the leukemic cell population might have been further reduced after 8 mo of maintenance chemotherapy.